Ultra Sensitive Diagnostic of Sepsis

Digital PCR-based test kit for rapid detection of pathogens and antibiotic resistance genes associated with sepsis. Provides comprehensive pathogen identification from blood samples within 2-3 hours.

CE-IVD certified dPCR assay for sensitive and rapid detection of key sepsis-causing pathogens, enabling timely clinical decision-making in critical care settings.

CE-IVD certified digital PCR assay for rapid detection of key sepsis-causing pathogens including bacteria and fungi. Enables timely clinical decision-making in intensive care and emergency settings.

Sensitive and fast dPCR-based assay for detecting key sepsis-causing pathogens, enabling clinicians to make timely diagnostic decisions. CE-IVD certified for clinical use.

Rapid diagnostic panel for identifying sepsis-causing pathogens and antimicrobial susceptibility at the bedside. Uses molecular and phenotypic analysis to enable fast, personalized antibiotic selection for critically ill patients. Delivers results within hours rather than days, supporting timely clinical decision-making in sepsis management.

Validated RT-PCR assay for rapid detection of 32 sepsis pathogens from whole blood in 90 minutes. Provides point-of-care molecular diagnostics for sepsis diagnosis.

High-sensitivity biomarker assay for early identification of sepsis in critically ill patients.

Rapid antibiotic susceptibility testing diagnostic system delivering results in hours instead of days for sepsis patients. Enables timely clinical intervention and appropriate antimicrobial selection.

Integrated diagnostic solutions for rapid sepsis pathogen identification and antimicrobial resistance profiling. The product line enables faster clinical decision-making in sepsis management.

Real-time PCR kits for rapid and accurate sepsis detection with the capability to simultaneously screen for antibiotic resistance genes. These kits are designed for time-critical sepsis diagnosis in clinical settings.

Patented technology delivering antibiotic susceptibility testing results in hours instead of days, enabling timely sepsis treatment intervention.

An FDA-cleared in vitro diagnostic test for adult patients with signs and symptoms of infection who present to the Emergency Department. The IntelliSep test runs on the Cytovale medical device to risk-stratify patients based on their probability of having sepsis with organ dysfunction manifesting within the first 3 days after testing. It provides test results in around 8 minutes by analyzing the immune response to infection through the biomechanical properties of white blood cells, enabling faster care and optimized patient outcomes.